Active, Not Recruiting
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
NCT03145181
- Conditions
- Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
- Locations
-
- City of Hope Duarte, California, United States
- Colorado Blood Cancer Institute Denver, Colorado, United States
- Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects New York, United States
- Levine Cancer Institute Charlotte, North Carolina, United States